Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04242953 · ClinicalTrials.gov registry record · Phase 1
Study to Determine Safety, Tolerability and Pharmacokinetics, of SCO-120 in Healthy Male and Post-menopausal Female Subjects
A Phase 1 study, sponsored by Sun Pharma Advanced Research Company Limited.
- Completed
- Registry status
- Phase 1
- Development phase
- 140
- Enrollment target
NCT04242953: Completed Phase 1 study, sponsored by Sun Pharma Advanced Research Company Limited.
NCT04242953 is a Phase 1 study that has completed, run by Sun Pharma Advanced Research Company Limited. The registered enrollment target is 140 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (133% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04242953, a Phase 1 study, has completed, sponsored by Sun Pharma Advanced Research Company Limited.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 140 participants
- Enrollment target
Study Summary
This is a Multipart Phase 1 Randomized, Double blind and Placebo controlled Study to Determine Safety, Tolerability and Pharmacokinetics, of SCO-120 in healthy male and postmenopausal female volunteers.
Primary Outcome
Part A: safety and tolerability assessed
Interventions
- DRUG matching placebo
- DRUG SCO-120
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 140 participants |
| Start Date | 2020-03-04 |
| Est. Completion | 2022-10-21 |
| Phase | Phase 1 |
What the finished NCT04242953 record still lists
NCT04242953 is an interventional study that assigns participants to a tested intervention. The registered 140 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (133% higher).
The record links to 0 conditions, and to 2 interventions - of which matching placebo is the first listed.
NCT04242953 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04242953 about?
NCT04242953 is a clinical study titled "Study to Determine Safety, Tolerability and Pharmacokinetics, of SCO-120 in Healthy Male and Post-menopausal Female Subjects". This is a Multipart Phase 1 Randomized, Double blind and Placebo controlled Study to Determine Safety, Tolerability and Pharmacokinetics, of SCO-120 in healthy male and postmenopausal female volunteers.
What is the current status of trial NCT04242953?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 140 participants. The study started on 2020-03-04. Estimated completion is 2022-10-21.
What interventions are being tested in trial NCT04242953?
The interventions under investigation include: matching placebo (DRUG), SCO-120 (DRUG).
Who is sponsoring clinical trial NCT04242953?
This trial is sponsored by Sun Pharma Advanced Research Company Limited, which has 20 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04242953's enrollment target sits among peer trials
140 402nd of 2000 higher than 1,583 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01419561 · 140 participants · Phase 2
Natural History Study of the KSHV Inflammatory Cytokine Syndrome (KICS)
- NCT01624805 · 140 participants · Phase 2
Methylprednisolone, Horse Anti-Thymocyte Globulin, Cyclosporine, Filgrastim, and/or Pegfilgrastim or Pegfilgrastim Biosimilar in Treating Patients With Aplastic Anemia or Low or Intermediate-Risk Myelodysplastic Syndrome
- NCT02369770 · 140 participants · NA
Sensory-Motor Rehabilitation Post Stroke
- NCT02455193 · 140 participants · NA
Neuronal Effects of Exercise in Schizophrenia
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI